Pharmacokinetics, safety, efficacy and immunogenicity of Adalimumab biosimilar ABP-501in rheumatoid arthritis and plaque psoriasis
This thesis is submitted in partial fulfillment of the requirements for the degree of Bachelor of Pharmacy, 2021.
Hlavní autor: | Akter, Anika |
---|---|
Další autoři: | Alam, Marzia |
Médium: | Diplomová práce |
Jazyk: | English |
Vydáno: |
Brac University
2022
|
Témata: | |
On-line přístup: | http://hdl.handle.net/10361/17039 |
Podobné jednotky
-
Biologics and Biosimilars as Treatment Options for Psoriasis
Autor: Moya, Amena Khatun
Vydáno: (2023) -
Importance of biologics in rheumatoid arthritis management
Autor: Riyadh, S. M.
Vydáno: (2022) -
TNF-α inhibitor-induced alopecia in psoriatic disease patients: a pharmacovigilance study
Autor: Afroza, Halima
Vydáno: (2024) -
Importance of biologically active agents over other therapies in Rheumatoid Arthritis- a review
Autor: Mehreen, Elnaj
Vydáno: (2021) -
A pharmacovigilance study on FDA approved interleukin inhibitor-associated alopecia in the treatment of psoriasis
Autor: Islam, Nahidul
Vydáno: (2023)